PL1877098T3 - Koniugaty estru alfa-aminokwasu z lekiem ulegające hydrolizie z udziałem karboksyloesterazy - Google Patents
Koniugaty estru alfa-aminokwasu z lekiem ulegające hydrolizie z udziałem karboksyloesterazyInfo
- Publication number
- PL1877098T3 PL1877098T3 PL06727008T PL06727008T PL1877098T3 PL 1877098 T3 PL1877098 T3 PL 1877098T3 PL 06727008 T PL06727008 T PL 06727008T PL 06727008 T PL06727008 T PL 06727008T PL 1877098 T3 PL1877098 T3 PL 1877098T3
- Authority
- PL
- Poland
- Prior art keywords
- carboxylesterase
- hydrolysable
- drug conjugates
- aminoacid ester
- alpha
- Prior art date
Links
- 102000013392 Carboxylesterase Human genes 0.000 title 1
- 108010051152 Carboxylesterase Proteins 0.000 title 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 title 1
- 235000008206 alpha-amino acids Nutrition 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0509226A GB0509226D0 (en) | 2005-05-05 | 2005-05-05 | Enzyme and receptor modulation |
| US68054205P | 2005-05-13 | 2005-05-13 | |
| EP06727008.2A EP1877098B1 (en) | 2005-05-05 | 2006-05-04 | Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase |
| PCT/GB2006/001635 WO2006117567A2 (en) | 2005-05-05 | 2006-05-04 | Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1877098T3 true PL1877098T3 (pl) | 2013-09-30 |
Family
ID=36609807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06727008T PL1877098T3 (pl) | 2005-05-05 | 2006-05-04 | Koniugaty estru alfa-aminokwasu z lekiem ulegające hydrolizie z udziałem karboksyloesterazy |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US20090215800A1 (pl) |
| EP (4) | EP1877098B1 (pl) |
| JP (2) | JP2008542196A (pl) |
| KR (1) | KR101332904B1 (pl) |
| AU (1) | AU2006243000B2 (pl) |
| BR (1) | BRPI0610368A8 (pl) |
| CA (1) | CA2607020C (pl) |
| IL (1) | IL186091A0 (pl) |
| MX (1) | MX2007013257A (pl) |
| PL (1) | PL1877098T3 (pl) |
| WO (1) | WO2006117567A2 (pl) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0509223D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| GB0608854D0 (en) * | 2006-05-04 | 2006-06-14 | Chroma Therapeutics Ltd | P13 kinase inhibitors |
| DK2013175T5 (da) * | 2006-05-04 | 2020-12-21 | Macrophage Pharma Ltd | p38 Map-kinase-inhibitorer |
| GB0608821D0 (en) * | 2006-05-04 | 2006-06-14 | Chroma Therapeutics Ltd | DHFR enzyme inhibitors |
| GB0608822D0 (en) * | 2006-05-04 | 2006-06-14 | Chroma Therapeutics Ltd | Inhibitors of DHFR |
| GB0608837D0 (en) | 2006-05-04 | 2006-06-14 | Chroma Therapeutics Ltd | Inhibitors of MAP kinase |
| GB0608823D0 (en) * | 2006-05-04 | 2006-06-14 | Chroma Therapeutics Ltd | Inhibitors of P13 kinase |
| GB0619753D0 (en) | 2006-10-06 | 2006-11-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| US8962825B2 (en) | 2006-10-30 | 2015-02-24 | Glaxosmithkline Intellectual Property Development Limited | Hydroxamates as inhibitors of histone deacetylase |
| GB0622084D0 (en) | 2006-11-06 | 2006-12-13 | Chroma Therapeutics Ltd | Inhibitors of HSP90 |
| US20100267774A1 (en) * | 2007-11-07 | 2010-10-21 | Chroma Therapeutics Ltd. | P38 map kinase inhibitors |
| GB0803747D0 (en) * | 2008-02-29 | 2008-04-09 | Martin | Enzyme and receptor modulation |
| ES2427892T3 (es) * | 2008-02-29 | 2013-11-04 | Chroma Therapeutics Limited | Inhibidores de MAP quinasa p38 |
| GB0903480D0 (en) | 2009-02-27 | 2009-04-08 | Chroma Therapeutics Ltd | Enzyme Inhibitors |
| US20110002897A1 (en) | 2009-06-11 | 2011-01-06 | Burnham Institute For Medical Research | Directed differentiation of stem cells |
| US9556426B2 (en) | 2009-09-16 | 2017-01-31 | Celgene Avilomics Research, Inc. | Protein kinase conjugates and inhibitors |
| CN102812167A (zh) | 2009-12-30 | 2012-12-05 | 阿维拉制药公司 | 蛋白的配体-介导的共价修饰 |
| GB201009853D0 (en) | 2010-06-11 | 2010-07-21 | Chroma Therapeutics Ltd | HSP90 inhibitors |
| GB201211310D0 (en) | 2012-06-26 | 2012-08-08 | Chroma Therapeutics Ltd | CSF-1R kinase inhibitors |
| HRP20171320T1 (hr) | 2012-10-17 | 2017-10-20 | Macrophage Pharma Limited | Terc-butil n-[2-{4-[6-amino-5-(2,4-difluorobenzoil)-2-oksopiridin-1(2h)-il]-3,5-difluorofenil}etil]-l-alaninat ili njegova sol, hidrat ili solvat |
| GB201504694D0 (en) * | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Covalent conjugates |
| WO2017216297A1 (en) | 2016-06-16 | 2017-12-21 | Glaxosmithkline Intellectual Property Development Limited | Dosage regimen |
| US10256877B2 (en) * | 2017-08-02 | 2019-04-09 | Qualcomm Incorporated | Apparatus and methods for beam refinement |
| GB201713975D0 (en) | 2017-08-31 | 2017-10-18 | Macrophage Pharma Ltd | Medical use |
| CN111303024B (zh) * | 2018-12-12 | 2023-03-28 | 安徽中科拓苒药物科学研究有限公司 | 一种喹啉结构的pan-KIT激酶抑制剂及其用途 |
| WO2024208705A1 (en) | 2023-04-02 | 2024-10-10 | The Francis Crick Institute Limited | Inhibitors of ets2-activating molecules for the treatment of inflammatory diseases |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1345502A (en) | 1972-07-06 | 1974-01-30 | Parke Davis & Co | Quinazoline compounds and processes for their production |
| US4725687A (en) * | 1986-04-28 | 1988-02-16 | Southern Research Institute | 5-methyl-5-deaza analogues of methotrexate and N10 -ethylaminopterin |
| US5175153A (en) * | 1987-11-30 | 1992-12-29 | Warner-Lambert Company | Substituted alpha-amino acids having pharmaceutical activity |
| US5331006A (en) * | 1990-08-31 | 1994-07-19 | Warner-Lambert Company | Amino acid analogs as CCK antagonists |
| AU666416B2 (en) * | 1993-01-29 | 1996-02-08 | Tanabe Seiyaku Co., Ltd. | Ellipticine derivative and process for preparing the same |
| US5480906A (en) * | 1994-07-01 | 1996-01-02 | Eli Lilly And Company | Stereochemical Wortmannin derivatives |
| EP0860433B1 (en) * | 1995-11-07 | 2002-07-03 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same |
| US7144902B1 (en) * | 1999-04-09 | 2006-12-05 | Abbott Gmbh & Co. Kg | Prodrugs of thrombin inhibitors |
| US6448256B1 (en) * | 1999-05-24 | 2002-09-10 | University Of Massachusetts | Antibiotic prodrugs |
| US6511990B1 (en) * | 1999-09-08 | 2003-01-28 | Sloan-Kettering Institute For Cancer Research | Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof |
| WO2002039997A2 (en) * | 2000-11-01 | 2002-05-23 | Millennium Pharmaceuticals, Inc. | Ace-2 modulating compounds and use thereof |
| KR20040099279A (ko) | 2002-02-22 | 2004-11-26 | 테바 파마슈티컬 인더스트리즈 리미티드 | 벤즈이속사졸 메탄 설포닐 클로라이드의 제조 방법 및조니사미드를 형성하기 위한 그의 아미드화 |
| AR038703A1 (es) * | 2002-02-28 | 2005-01-26 | Novartis Ag | Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3 |
| EP2322160A1 (en) * | 2002-03-04 | 2011-05-18 | Merck HDAC Research, LLC | Methods of inducing terminal differentiation |
| WO2003076405A1 (en) * | 2002-03-14 | 2003-09-18 | Bayer Healthcare Ag | Monocyclic aroylpyridinones as antiinflammatory agents |
| JP2006512318A (ja) | 2002-11-12 | 2006-04-13 | アルコン,インコーポレイテッド | 眼の血管新生もしくは水腫状の疾患および障害を処置するためのヒストンデアセチラーゼインヒビター |
| CN101123878A (zh) * | 2003-07-29 | 2008-02-13 | 信号研发控股有限责任公司 | 氨基酸前药 |
| JP2007509082A (ja) * | 2003-10-22 | 2007-04-12 | アルピダ エー/エス | ペプチドデホルミラーゼ阻害剤としてのベンゾイミダゾール誘導体類およびそれらの使用 |
| EP1718145A4 (en) * | 2004-02-02 | 2012-03-07 | Biosight Ltd | CONJUGATES FOR CANCER THERAPY AND DIAGNOSIS |
| TW200536528A (en) * | 2004-02-27 | 2005-11-16 | Schering Corp | Novel inhibitors of hepatitis C virus NS3 protease |
| JP4993374B2 (ja) * | 2004-04-05 | 2012-08-08 | メルク エイチディーエーシー リサーチ エルエルシー | ヒストン脱アセチル化酵素インヒビタープロドラッグ |
| ES2299080T3 (es) * | 2004-05-14 | 2008-05-16 | Millennium Pharmaceuticals, Inc. | Compuestos y metodos para inhibir la progresion mitotica mediante la inhibicion de quinasas aurora. |
| GB0509227D0 (en) * | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Intracellular enzyme inhibitors |
| GB0509225D0 (en) * | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Inhibitors of enzymatic activity |
| GB0509224D0 (en) * | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Inhibitors of intracellular enzymatic activity |
| GB0509223D0 (en) * | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| GB0619753D0 (en) * | 2006-10-06 | 2006-11-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| GB0621830D0 (en) * | 2006-11-02 | 2006-12-13 | Chroma Therapeutics Ltd | Inhibitors of p38 mitogen-activated protein kinase |
-
2006
- 2006-05-04 AU AU2006243000A patent/AU2006243000B2/en not_active Ceased
- 2006-05-04 EP EP06727008.2A patent/EP1877098B1/en active Active
- 2006-05-04 WO PCT/GB2006/001635 patent/WO2006117567A2/en not_active Ceased
- 2006-05-04 EP EP20080075301 patent/EP1964578A3/en not_active Ceased
- 2006-05-04 PL PL06727008T patent/PL1877098T3/pl unknown
- 2006-05-04 JP JP2008509506A patent/JP2008542196A/ja active Pending
- 2006-05-04 CA CA2607020A patent/CA2607020C/en active Active
- 2006-05-04 EP EP19156158.8A patent/EP3530290A1/en not_active Withdrawn
- 2006-05-04 KR KR1020077023742A patent/KR101332904B1/ko not_active Expired - Fee Related
- 2006-05-04 US US11/918,138 patent/US20090215800A1/en not_active Abandoned
- 2006-05-04 BR BRPI0610368A patent/BRPI0610368A8/pt not_active Application Discontinuation
- 2006-05-04 MX MX2007013257A patent/MX2007013257A/es active IP Right Grant
- 2006-05-04 EP EP08075300.7A patent/EP1964577B1/en not_active Not-in-force
-
2007
- 2007-09-20 IL IL186091A patent/IL186091A0/en unknown
-
2013
- 2013-07-02 JP JP2013139093A patent/JP2013241423A/ja active Pending
-
2014
- 2014-10-07 US US14/508,248 patent/US20150126534A1/en not_active Abandoned
-
2017
- 2017-07-14 US US15/650,031 patent/US20180000952A1/en not_active Abandoned
-
2019
- 2019-01-24 US US16/255,947 patent/US20190231887A1/en not_active Abandoned
-
2021
- 2021-05-21 US US17/326,470 patent/US20210361772A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL186091A0 (en) | 2008-01-20 |
| CA2607020A1 (en) | 2006-11-09 |
| CA2607020C (en) | 2015-01-13 |
| EP1964578A2 (en) | 2008-09-03 |
| EP1877098B1 (en) | 2013-04-24 |
| US20180000952A1 (en) | 2018-01-04 |
| KR101332904B1 (ko) | 2013-11-26 |
| KR20080003809A (ko) | 2008-01-08 |
| EP1877098A2 (en) | 2008-01-16 |
| BRPI0610368A8 (pt) | 2015-09-08 |
| EP1964577A2 (en) | 2008-09-03 |
| WO2006117567A2 (en) | 2006-11-09 |
| US20150126534A1 (en) | 2015-05-07 |
| JP2013241423A (ja) | 2013-12-05 |
| JP2008542196A (ja) | 2008-11-27 |
| WO2006117567A3 (en) | 2007-08-30 |
| US20090215800A1 (en) | 2009-08-27 |
| EP1964578A3 (en) | 2008-11-05 |
| AU2006243000A1 (en) | 2006-11-09 |
| BRPI0610368A2 (pt) | 2010-06-15 |
| EP1964577A3 (en) | 2008-11-05 |
| EP1964577B1 (en) | 2016-04-13 |
| US20210361772A1 (en) | 2021-11-25 |
| US20190231887A1 (en) | 2019-08-01 |
| AU2006243000B2 (en) | 2011-05-26 |
| MX2007013257A (es) | 2008-01-21 |
| EP3530290A1 (en) | 2019-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL1877098T3 (pl) | Koniugaty estru alfa-aminokwasu z lekiem ulegające hydrolizie z udziałem karboksyloesterazy | |
| AP2436A (en) | Immunogenic composition | |
| GB0504436D0 (en) | Vaccine | |
| ZA200709518B (en) | Vaccine composition | |
| GB0526038D0 (en) | Immunogenic composition | |
| ZA200710853B (en) | Immunogenic composition | |
| GB0810662D0 (en) | Vaccine | |
| GB0515135D0 (en) | Vaccine | |
| GB0516944D0 (en) | Vaccine | |
| ZA200708283B (en) | Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase | |
| ZA200710854B (en) | Immunogenic composition | |
| GB0526412D0 (en) | Vaccine | |
| GB0502569D0 (en) | Vaccine composition | |
| GB0515556D0 (en) | Immunogenic composition | |
| GB0524204D0 (en) | Immunogenic composition | |
| GB0526041D0 (en) | Immunogenic composition | |
| GB0503143D0 (en) | Immunogenic composition | |
| IL186586A0 (en) | Vaccine | |
| GB0523445D0 (en) | Vaccine | |
| GB0526232D0 (en) | Vaccine | |
| GB0503000D0 (en) | Anti-atheroma vaccine | |
| GB0509010D0 (en) | Vaccine | |
| GB0513191D0 (en) | Vaccine | |
| GB0513194D0 (en) | Vaccine | |
| GB0521164D0 (en) | Vaccine |